Alector to Host Virtual Research and Development Event Highlighting PGRN Franchise and Brain Carrier Programs
Alector (Nasdaq: ALEC) announced a virtual R&D event scheduled for September 22, 2025, focusing on their progranulin (PGRN) franchise and Alector Brain Carrier (ABC) programs. The presentation will highlight two key clinical programs: latozinemab, in Phase 3 trials for frontotemporal dementia, and AL101, in Phase 2 trials for early Alzheimer's disease.
The event will also showcase preclinical data from their ABC-enabled programs, including a brain-penetrant anti-amyloid beta antibody for Alzheimer's and a GCase-enzyme replacement therapy for Parkinson's disease. Additionally, updates on ABC-enabled siRNA programs will be presented, demonstrating the platform's versatility in treating neurodegenerative diseases.
Alector (Nasdaq: ALEC) ha annunciato un evento virtuale di ricerca e sviluppo fissato per 21 settembre 2025, incentrato sulla loro franchise di progranulina (PGRN) e sui programmi Alector Brain Carrier (ABC). La presentazione metterà in risalto due programmi clinici chiave: latozinemab, attualmente in fase 3 per la demenza frontotemporale, e AL101, in fase 2 per la malattia di Alzheimer in fase iniziale.
L’evento presenterà anche dati preclinici sui programmi abilitati da ABC, tra cui un anticorpo anti-aggregato beta proteico capace di penetrare nel cervello per l’Alzheimer e una terapia di sostituzione dell’enzima GCase per la malattia di Parkinson. Inoltre, verranno forniti aggiornamenti sui programmi siRNA abilitati da ABC, dimostrando la versatilità della piattaforma nel trattamento delle malattie neurodegenerative.
Alector (Nasdaq: ALEC) anunció un evento virtual de I+D programado para el 22 de septiembre de 2025, centrado en su franquicia de progranulina (PGRN) y en los programas Alector Brain Carrier (ABC). La presentación destacará dos programas clínicos clave: latozinemab, en ensayos de fase 3 para la demencia frontotemporal, y AL101, en ensayos de fase 2 para la enfermedad de Alzheimer en etapa temprana.
El evento también mostrará datos preclínicos de los programas habilitados por ABC, incluida una anticuerpo anti-amyloid beta que penetra el cerebro para la enfermedad de Alzheimer y una terapia de reemplazo enzimático de GCase para la enfermedad de Parkinson. Además, se presentarán actualizaciones sobre los programas de siRNA habilitados por ABC, demostrando la versatilidad de la plataforma para tratar enfermedades neurodegenerativas.
Alector (나스닥: ALEC)은 2025년 9월 22일로 예정된 가상 연구개발 이벤트를 발표했습니다. 이 이벤트는 그들의 프로그란울린(PGRN) 프랜차이즈와 Alector Brain Carrier(ABC) 프로그램에 초점을 맞추며, 프레젠테이션은 두 가지 주요 임상 프로그램을 강조합니다: latozinemab은 뇌전증 전형의 전임상 3상으로, AL101은 초기 알츠하이머병의 2상으로 진행 중입니다.
또한 이번 행사는 ABC로 가능하게 된 프로그램의 전임상 데이터를 선보일 예정이며, 알츠하이머병을 위한 뇌 침투성 아밀로이드 베타 항체와 파킨슨병에 대한 GCase 효소 대체 요법이 포함됩니다. 더불어 ABC 활성화 siRNA 프로그램에 대한 업데이트도 발표되어, 신경퇴행성 질환 치료에 있어 플랫폼의 다재다능함을 시연합니다.
Alector (Nasdaq: ALEC) a annoncé un événement virtuel de recherche et développement prévu le 22 septembre 2025, axé sur leur franchise de progranuline (PGRN) et les programmes Alector Brain Carrier (ABC). La présentation mettra en évidence deux programmes cliniques clés : latozinemab, en essais de phase 3 pour la démence frontotemporale, et AL101, en essais de phase 2 pour la maladie d’Alzheimer à un stade précoce.
L’événement mettra également en avant des données précliniques des programmes habilités par ABC, notamment un anticorps anti-amyloid bêta capable de pénétrer dans le cerveau pour la maladie d’Alzheimer et une thérapie de remplacement enzymatique de GCase pour la maladie de Parkinson. Des mises à jour sur les programmes siRNA activés par ABC seront également présentées, démontrant la polyvalence de la plateforme dans le traitement des maladies neurodégénératives.
Alector (Nasdaq: ALEC) hat eine virtuelle F&E-Veranstaltung angekündigt, die am 22. September 2025 stattfinden soll und sich auf das Progranulin-Portfolio (PGRN) sowie die Alector Brain Carrier (ABC)-Programme konzentriert. Die Präsentation wird zwei wichtige klinische Programme hervorheben: latozinemab, in Phase-3-Studien zur frontotemporalen Demenz, und AL101, in Phase-2-Studien zur frühen Alzheimerkrankheit.
Die Veranstaltung wird außerdem präklinische Daten zu ABC-gestützten Programmen vorstellen, darunter einen blut-hirndurchdringenden Anti-Amyloid-Beta-Antikörper für Alzheimer sowie eine GCase-Enzymersatztherapie für Parkinson. Zudem werden Updates zu ABC-gestützten siRNA-Programmen präsentiert, die die Vielseitigkeit der Plattform bei der Behandlung neurodegenerativer Erkrankungen demonstrieren.
Alector (ناسداك: ALEC) أعلن عن حدث افتراضي للبحث والتطوير مقرر في 22 سبتمبر 2025 يركّز على امتياز بروجرانولين PGRN وبرامج Alector Brain Carrier (ABC). ستسلط العرض الضوء على برنامجين سريريين رئيسيين: latozinemab، في تجارب المرحلة 3 لمرض الخَرْفُ الرُعاشي الأمامي (FTD)، وAL101، في تجارب المرحلة 2 لمرض الزهايمر في مُبكّره.
سيعرض الحدث أيضاً بيانات ما قبل السريرية من البرامج المُمكَّنة بـ ABC، بما في ذلك جسم مضاد مضاد أميلويد بيتا يمكنه اختراق الدماغ للعلاج من الزهايمر وعلاج استبدال الإنزيم GCase لمرض باركنسون. بالإضافة إلى ذلك، ستقدم تحديثات حول برامج siRNA المدعومة بـ ABC، مما يبرز تنوع المنصة في علاج أمراض الجهاز العصبي المُتْلاَزِمة.
Alector（纳斯达克：ALEC）宣布将于2025年9月22日举行一个虚拟研发活动，聚焦于他们的前程核糖体素（PGRN）系列以及ABC（Alector Brain Carrier）计划。此次演讲将重点介绍两个关键临床项目：latozinemab，处于前额叶叶部痴呆的3期试验阶段，以及
活动还将展示ABC支持计划的前临床数据，包括一种能穿透大脑的抗淀粉样β抗体用于阿尔茨海默病，以及用于帕金森病的GCase酶替代治疗。此外，还将介绍ABC支持的siRNA计划的更新，展示该平台在治疗神经退行性疾病方面的多功能性。
- None.
- None.
--Agenda to feature latozinemab and AL101, along with progress in Alector Brain Carrier–enabled programs, including new lead candidates--
SOUTH SAN FRANCISCO, Calif., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced management will host a virtual event to discuss the company’s progranulin (PGRN) franchise and Alector Brain Carrier (ABC)–enabled programs. The event will include a review of latozinemab, currently being evaluated in a pivotal Phase 3 trial for frontotemporal dementia due to a GRN gene mutation, and AL101, which is in a Phase 2 trial for early Alzheimer’s disease (AD). In addition, the company will present preclinical data on lead candidates for its ABC–enabled programs, including its brain-penetrant anti-amyloid beta antibody program for AD, and its brain-penetrant engineered GCase-enzyme replacement therapy for Parkinson’s disease. The event will also highlight progress in Alector’s ABC-enabled siRNA programs, which expand the platform’s reach across different cargos for the treatment of neurodegenerative diseases.
Details of the webinar are as follows:
Alector R&D Briefing: A Review of Our PGRN Franchise and Brain Carrier Programs
Monday, September 22, 2025, from 12:00 to 1:30 pm EDT
A live question and answer session will follow the formal presentation. To access the live webcast of this event, please register here, or visit “Events and Presentations” in the “Investors” section of the Alector website at https://investors.alector.com. An archived replay will be available for approximately 90 days following the presentation.
About Alector
Alector is a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegenerative diseases. Leveraging the principles of genetics, immunology, and neuroscience, the company is advancing a portfolio of genetically validated programs that aim to remove toxic proteins, replace deficient proteins, and restore immune and nerve cell function. Supported by biomarkers, Alector’s product candidates seek to treat a range of indications, such as frontotemporal dementia, Alzheimer’s disease, and Parkinson's disease. The company is also developing Alector Brain Carrier (ABC), a proprietary blood-brain barrier platform, which is being selectively applied to its next-generation product candidates and research pipeline. ABC aims to enhance the delivery of therapeutics, achieve deeper brain penetration and efficacy at lower doses, and ultimately improve patient outcomes while reducing costs. Alector is headquartered in South San Francisco, California. For more information, please visit www.alector.com.
Alector Contacts:
Alector
Katie Hogan
202-549-0557
katie.hogan@alector.com
Argot Partners (media)
David Rosen
646-461-6387
alector@argotpartners.com
Argot Partners (investors)
Laura Perry
212-600-1902
alector@argotpartners.com
FAQ
When is Alector's (ALEC) R&D event and how can investors access it?
What clinical programs will Alector (ALEC) discuss during the R&D event?
What are the key preclinical programs in Alector's (ALEC) Brain Carrier platform?
How long will Alector's (ALEC) R&D presentation be available for replay?
